



NETSCC, HTA

26 January 2012

PROTOCOL

Physical Activity programmes for community dwelling people with mild to moderate dementia

Dementia And Physical Activity - DAPA

ISRCTN Number: ISRCTN32612072

Funding Body: NIHR HTA 09/80/04

Ethics Approval:


Version Number 1.1

Date 23rd November 2011

Stage Final

Protocol Amendments:

Amendment No.	Date of Amendment	Date of Approval
---------------	-------------------	------------------



CONTACT NAMES AND NUMBERS

Role	Name, address, telephone
Sponsor	Dr Peter Hedges Warwick Medical School The University of Warwick Gibbet Hill Road, CV4 7AL Tel: 024 7652 3859 Email: P.A.Hedges@warwick.ac.uk
Chief Investigator	Professor Sallie Lamb Director Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Road, CV4 7AL Tel: 024 7657 4658 Email: s.lamb@warwick.ac.uk
Trial Coordinator	Dr Sukhi Dosanjh Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Road, CV4 7AL Tel: 024 7615 0955 Fax: 024 7657 4657 Email: S.Dosanjh@warwick.ac.uk

Role	Name, address, telephone	
Co-Investigators	Dr Bart Sheehan The University of Warwick Gibbet Hill Road, Coventry, CV4 7AL Tel: 02476 574387 Email: b.sheehan@warwick.ac.uk	Dr Anne-Marie Slowther Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Road, Coventry, CV4 7AL Tel: 02476 574513 Email: anne- marie.slowther@warwick.ac.uk
	Prof Margaret Thorogood The University of Warwick Gibbet Hill Road, Coventry, CV4 7AL Tel: 02476 574509 Email: m.thorogood@warwick.ac.uk	Dr Frances Griffiths The University of Warwick Gibbet Hill Road, Coventry, CV4 7AL Tel: 02476 522534 Email: f.e.griffiths@warwick.ac.uk
	Dr Ranjit Lall Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Road, Coventry, CV4 7AL Tel: 02476 574649 Email: r.lall@warwick.ac.uk	Prof Stavros Petrou Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Road, Coventry, CV4 7AL Tel: 02476 151124 Email: S.petrou@warwick.ac.uk
	Dr Rupert McShane John Radcliffe Hospital Headington Oxford, OX3 9DU Tel: 01865 234306 Email: Rupert.mcshane@obmh.nhs. uk	Dr Chris Bridle Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Road, Coventry, CV4 7AL Tel: 02476 150222 Email: c.bridle@warwick.ac.uk
Randomisation	Tel: 024 765 150402 (Mon-Fri, 9am to 5pm) Fax: 024 765 150549	

Table of Contents

LIST OF ABBREVIATIONS.....	6
1. BACKGROUND.....	7
1.1 Epidemiology and burden of the condition	7
1.2 Existing knowledge	7
1.3 Research Objectives	9
1.4 Good Clinical Practice	9
2. TRIAL DESIGN.....	9
2.1 Trial summary	9
2.2 Objectives	11
2.2.1 Primary objective	11
2.2.2 Secondary objective	11
2.3 Outcome Measures.....	11
2.3.1 Primary	11
2.3.2 Others.....	11
2.4 Power and Sample Size	12
2.5 Eligibility Criteria	13
2.5.1 Inclusion criteria.....	13
2.5.2 Exclusion criteria	13
2.6 Informed Consent.....	13
2.7 Recruitment and Randomisation.....	14
2.8 Post-randomisation withdrawals and exclusions.....	15
2.9 Blinding	15
2.9.1 Methods for ensuring blinding	15
2.10 Trial Intervention / Treatments	15
2.10.1 Trial Treatment(s) / Intervention	15
2.10.2 Compliance/Contamination	18
3. METHODS AND ASSESSMENTS.....	19
3.1 Schedule of intervention and data collection.....	19
4. ADVERSE EVENT MANAGEMENT	20
4.1 Definitions.....	20
4.1.1 Adverse Events (AE).....	20
4.1.2 Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Events.....	20
4.2 Reporting SAEs	20
4.3 End of Trial	20
5. DATA MANAGEMENT	21

5.1	Data collection and management.....	21
5.2	Database	21
5.3	Data Storage	21
5.4	Archiving	22
6.	STATISTICAL ANALYSIS.....	22
7.	TRIAL ORGANISATION AND OVERSIGHT	23
7.1	Ethical conduct of the trial	23
7.2	Sponsor.....	24
7.3	Indemnity.....	24
7.4	Trial timetable and milestones	24
7.5	Administration.....	25
7.6	Trial Management Group (TMG)	25
7.7	Trial Steering Committee (TSC).....	25
7.8	Data Monitoring and Ethics Committee (DMEC).....	26
7.9	Essential Documentation	26
8.	MONITORING AND QUALITY ASSURANCE OF TRIAL PROCEDURES	26
9.	DISSEMINATION AND PUBLICATION	27
10.	FINANCIAL SUPPORT.....	27
11.	PROTOCOL AMENDMENTS.....	27
12.	REFERENCES.....	28
13.	APPENDICES	31

LIST OF TABLES	PAGE
Table 1 Trial events	12

LIST OF FIGURES	PAGE
Figure 1 Trial flow diagram	10

LIST OF APPENDICES	
Appendix A Project timetable.....	31

LIST OF ABBREVIATIONS

Abbreviation	Explanation
AE	Adverse event
BADL	Bristol Activities of Daily Living
BDNF	Brain derived neurotrophic factor
CRF	Case Report Form
CSSD	Cornell Scale for Depression in Dementia
CTU	Clinical Trials Unit
DeNDRoN	Dementia and Neurodegenerative Disease Research Network
DMEC	Data Monitoring and Ethics Committee
DSM	Diagnostic and Statistical Manual
GCP	Good Clinical Practice
ICH	International Conference on Harmonisation
MCI	Mild cognitive impairment
MMSE	Mini Mental State Examination
MRC	Medical Research Council
MREC	Multicentre Research Ethics Committee
NICE	National Institute for Health and Clinical Excellence
NPI	Neuropsychiatric Inventory
PWD	Person with Dementia
QOL	Quality of Life
ROS	Reactive Oxygen Species
R&D	Research and Development
SAE	Serious adverse event
SOP	Standard Operating Procedure
TSC	Trial Steering Committee
WCTU	Warwick Clinical Trials Unit
ZBI	Zarit Burden Interview

1. BACKGROUND

1.1 Epidemiology and burden of the condition

Dementia is a syndrome characterized by acquired progressive deterioration in memory, general cognitive function, self-care and personality. About half of cases are caused by Alzheimer's disease, while vascular dementia, mixed Alzheimer/Vascular dementia and Dementia with Lewy bodies are the other common causes. Mild dementia should be distinguished from mild cognitive impairment (MCI), a term used for people who experience more cognitive impairment than would be expected for their age, but unlike dementia, the impairment is not so severe as to interfere with activities of daily living. Although MCI is a risk factor for dementia, many people with MCI do not progress to dementia.

In the UK, it is estimated that more than 800,000 people have dementia, with an annual cost to the UK economy of £23 billion (Luengo-Fernandez et al 2010). In the next 30 years the number of people with dementia will double and costs will treble to more than £50 billion pa. Although the recent national dementia strategy for the UK (NDS 2009) calls for a focus on early diagnosis, treatment options for dementia are relatively limited, with no new drugs available since 2002. NICE (NICE 2011) recommends cholinesterase inhibitors (donepezil, galantamine and rivastigmine), but only for mild to moderate Alzheimer's disease (not for vascular dementia). The only other drug licensed in the UK is memantine, but is supported by NICE only for limited use in moderate to severe dementia, or in patients unable to tolerate cholinesterase inhibitors. In reality, for many people with mild to moderate dementia, a major focus of services after diagnosis is on carer training, family support, and indirect interventions to alleviate risk, such as home carers, day care, respite admissions, sitting services and carer support services.

1.2 Existing knowledge

The protective effects of moderate levels of physical activity on the progression of (subjective memory impairment) and mild cognitive impairment to dementia have been observed consistently in several large scale epidemiological studies (Geda et al 2010; Etgen et al 2010; Erikson et al 2009). Studies of transgenic Alzheimer mice and dogs suggest several potential mechanisms by which exercise may prevent the progression of dementia. Brain derived neurotrophic factor (BDNF) is stimulated by exercise in Alzheimer mice, leading to increased concentrations in many areas of the brain, including the hippocampus which is thought to have a key role in mediating some of the effects of dementia. In animal dementia models, effects on BDNF are observed 3-4 weeks after initiation of exercise, and translate into improvements in spatial memory which last for some period of time, but in the absence of an on-going exercise stimulus, begin to decline thereafter. Other effects of exercise include improved synaptic function, increased blood flow and neurogenesis (potentially of importance for the vascular dementias), stimulation of anabolic metabolism, improved mitochondrial ROS production and reduction of damaging beta amyloid effects. Encouragingly, recent epidemiological studies of autopsied human brain have shown positive associations between physical activity and the volume of the hippocampus and other areas of the central nervous system sensitive to pathological change in dementia, all of which are targets considered

important for treatment (Deslandes et al 2009).

These studies provide encouraging evidence, and some guide to the type, dose and duration of exercise required to benefit people with, or at risk of, dementia. Moderate intensity activity is the prime candidate, defined as exercise 3 times a week. Animal model studies are limited to aerobic type exercise which raises the heart rate and blood flow. Interventional studies in humans are scarce, but a few, predominantly in mild cognitive impairment and memory impairment, provide important data to guide the development of an exercise programme. The most pertinent Cochrane Review (Forbes et al. 2008) included 4 studies, but could draw no conclusion about the effectiveness of interventions. Since the last update (2007/8) Baker et al tested high intensity aerobic training (>75% of heart rate max, 4* times a week, ~ 1hr per session, 6 months) in people with mild cognitive impairment, demonstrating improvements in biomarkers associated with Alzheimer's as well as tests of executive and other aspects of cognitive function. There was some evidence of a differential effect between men and women. No follow up data have been published and the sustainability is unknown.

Supervised walking programmes are possible for people with mild cognitive impairment, but have not been tested in people with more established dementia. In a randomised controlled trial of a year long, twice weekly walking programme, there was no overall benefit in terms of cognitive function, although the effect may vary by gender (Weuve et al 2004; Abbott et al 2004). Lautenschlager et al (2008) studied people with subjective memory impairment (a precursor to Alzheimer's disease) and demonstrated modest improvements in cognition resulting from a 24 week physical activity intervention. Encouragingly, improvements were sustained over an 18 month follow up period. In a pilot for the LIFE study, which is testing twice weekly physical activity over a 12 month period, improving physical activity was related to improvements in cognitive status in people with normal cognition (LIFE Study Team 2006).

Resistance (or strength) training is an important component of many interventions targeted at geriatric syndromes (of which cognitive impairment is one), but has received less attention. Strength training may improve cognition by altering levels of homocysteine and insulin like growth factor 1, but more importantly, will improve physical functioning, reduce fall risk, agitation and possibly some behavioural problems (Liu Ambrose et al 2009). Logsdon et al (2009) have reviewed approaches to making physical activity accessible to older adults with memory loss, using many techniques that we currently use within our OPERA intervention.

Although much of the current evidence informing the choice of type of exercise to improve cognition is derived from animal studies, and studies of healthy humans or people with MCI, it is widely recognised that exercise has the potential to be a very important intervention in the management of people with dementia. Exercise will improve physical fitness and functioning, and selection of the right type of exercise stimulus can reduce fall risk, improve mobility and reduce cardiovascular risk factors, just as in people who are not cognitively impaired.

Systematic reviews

For the DAPA study, we will carry out a systematic review of interventions to improve cognition through exercise. We will investigate issues of dose of exercise by extracting information on duration, intensity and type of exercise provided. As before, we will adhere to best practice in carrying out systematic reviews (Higgins & Green 2009). As depression and cognitive impairment are linked, and share similar biological pathways (and based on our knowledge of the literature), we do not anticipate that the intervention will change substantially as a result of this new review (see below for links to previous trial).

1.3 Research Objectives

Our objectives are to:

1. Refine an existing intervention for delivery to community dwelling populations of people with dementia, including an update/expansion of a systematic review completed as part of the HTA funded Older People's Exercise in Residential Accommodation (OPERA (HTA 06/02/01)) trial and user involvement processes.
2. Pilot critical procedures prior to the trial.
3. Complete a definitive, individually randomised controlled trial to estimate the effectiveness of the DAPA programme in addition to usual care on *cognitive impairment* (primary outcome), *function and quality of life* (secondary outcomes) in people with mild or moderate dementia, and for carers, carer burden (secondary outcome).

1.4 Good Clinical Practice


The trial will be carried out in accordance with the Medical Research Council (MRC) Good Clinical Practice Guidelines, and applicable UK legislation.

2. TRIAL DESIGN

2.1 Trial summary

The DAPA trial aims to establish whether exercise is effective in treating against functional and cognitive decline in community dwelling adults with mild to moderate dementia. It is a randomised controlled trial comparing an additional structured exercise regimen to best practice usual care. The trial will include a pilot phase for the refinement of an existing intervention previously used in the OPERA trial (ISRCTN43769277). The structured exercise intervention will be carried out over a 4 month period with a transition to community based sustainable physical activity.

Figure 1 **Trial flow diagram**



2.2 Objectives

2.2.1 Primary objective

The primary objective of this trial is to undertake a definitive randomised controlled trial to estimate the effects of an exercise/physical activity intervention that is feasible for delivery within the current constraints of National Health Service delivery.

2.2.2 Secondary objective

Secondary objectives of the study are to

- Complete a parallel cost study and conduct an economic analysis from a healthcare and societal perspective.
- Investigate intervention effects in pre-defined sub-groups of gender and dementia severity.

2.3 Outcome Measures

2.3.1 Primary

The primary outcome measures will be cognition and function.

Dementia is a complex multi-faceted condition with deterioration in multiple domains. Cognitive deterioration is recognised as a core feature of the condition, and leads to deterioration in functional ability. Both cognition and functional deterioration have been shown to predict carer stress and increased costs in dementia, and hence function is also an important outcome. Cognitive function will be measured using a well validated and widely used measure, the Mini Mental State Examination (MMSE Folstein et al 1975). Function will be measured using the Bristol Activity of Daily Living scale (BADL Bucks et al 1996). Both scales have established validity and sensitivity to change, and have been used widely in interventional research studies in dementia (Black et al 2009). Existing data allow clear predictions of deterioration over time in both scales, and calculation of clinically important differences between groups (Molner et al 2009).

The outcomes are all among those recommended by a consensus recommendation of outcome scales for non-drug interventional studies in dementia (Moniz-Cook et al 2008). We will test the acceptability of the outcome measure package in the pilot study, including issues concerning the need for, and consistency of, proxy completion.

2.3.2 Others

Other outcomes will include:

- Health-related quality of life (Euro-QoL [EQ-5D] EuroQoL Group 1990)
- Dementia quality of life (Quality of Life in Alzheimer's Disease [QoL-AD] Logsdon et al 1999),
- Behavioural symptoms (Neuropsychiatric Inventory [NPI] Cummings et al 1994),
- Mood (Cornell Scale for Depression in Dementia [CSDD] Alexopoulos et al 1988), and
- Carer burden (Zarit Burden Interview [ZBI] Zarit et al 1980).

- Self-reported falls and fractures.

2.4 Power and Sample Size

Proposed sample size

Determining the clinically important difference between groups is a challenge for all trials. Small to moderate effect sizes will be important in this context since the intervention is likely to be reasonably priced, and hence small benefits are likely to be cost-effective at current levels of willingness to pay. Taking a guide from trials of Donepezil versus placebo, the overall difference estimated from 8 trials was 1.3 MMSE points, and this is considered widely to be a clinically worthwhile target. A slowing of decline of 1 MMSE point over 12 months could mean a delay in dementia progression of up to 7 months for people with mild dementia, and up to 5 months in moderate dementia. The usual standard deviation for the MMSE in similar US cohorts is 5 to 5.5 (Rockwood et al 2007), which we have validated against published data from UK memory clinics (mean SD 5.2) (Brown 2009; Lindesay 2002; Luce 2001).

We have used a between group difference of 1.3 MMSE points, baseline standard deviation of 5 (equating to a standardised effect size of 0.26), 80% power, $p < 0.05$, and inflation to account for therapist effects using an ICC of 0.01. This estimate of therapist effect is taken from a range of trials of group based interventions in low back pain, and will be updated with information from the OPERA study when this becomes available. The number of cases needed for final analysis at 12 months is 510. We have inflated to account for a loss to follow up of 30%, including 10% attrition attributable to death, yielding a target sample size of 728 participants. The trial has satisfactory power ($\geq 80\%$) to detect clinically important differences in the secondary outcomes.

Participant pool: We have identified and agreed collaborations with 7 community dementia services (Coventry, Rugby, Nuneaton, Amersham, Oxfordshire, Northampton and High Wycombe), and obtained precise data from 5 of these services in order to estimate the pool of potential participants (Table 1).

Table 1: Patient flow from five of the proposed study recruitment sites

Patient group	Rugby	Nuneaton	Coventry	Amersham	Oxon	Total
Attendances pa	400	670	1000	700	600	3370
MMD (75%)	300	500	750	525	450	2525
Eligible (70%)	210	350	525	370	315	1770
Recruitment (30%)	63	105	158	111	95	532

We estimate that over the course of 12 months, the 7 collaborating services would have routine contact with 4650 people with mild to moderate dementia (Figure 1). Based on estimates provided by the services we would expect that at least 3488 (75%) of people will have mild to moderate dementia. Eligibility criteria are quite simple, and should not restrict enrolment into the trial, and of those with mild or moderate dementia, the majority (2441,

70%) would be eligible for enrolment. We have estimated a 30% uptake rate of the invitation to participate, which will be confirmed during the pilot phase ($n \geq 728$ (exact = 732)).

2.5 Eligibility Criteria

2.5.1 Inclusion criteria

Potential participants will be eligible for inclusion if they meet each of the following criteria:

1. Probable dementia according to the Diagnostic and Statistical Manual, 4th Edition (DSM IV) criteria:
 - a. Memory impairment with cognitive disturbance in at least one of the following domains - aphasia (language), apraxia (motor activities), agnosia (object recognition) or executive functioning (planning, sequencing, abstracting)
 - b. Functional decline: increasing impairment in functional ability (social, occupational, personal/self-care) related to cognitive deficits.
2. Probable dementia of mild to moderate severity (MMSE >10).
3. Are able to participate in a structured exercise programme:
 - a) able to sit on a chair and to walk 10 feet without human assistance;
 - b) no serious unstable illness (e.g. unstable angina)
4. Live in the community, either alone or with a relative, friend, or carer, or in sheltered accommodation.

2.5.2 Exclusion criteria

1. People with severe dementia (MMSE ≤ 10) will not be eligible for inclusion.
2. Acute, unstable or terminal illness which would make participation in the exercise group impractical.
3. People living in residential nursing homes will not be eligible for inclusion.

2.6 Informed Consent

The main ethical issue in this trial is that some people with mild to moderate dementia will lack the necessary mental capacity to give informed consent. As is routine in dementia trials, however, patients who lack capacity to consent can agree to participate and, in compliance with the Mental Capacity Act (2005), advice is obtained from a personal consultee. For those relatively few participants unable to give informed consent, and for whom no personal consultee is available, an attempt will be made to find a nominated consultee. The most common route for a nominated consultee might be an independent mental capacity advocate (IMCA). Experience in other trials suggests IMCAs are rarely willing to consider this role. If this is the case, an alternative professional (e.g. GP) who is entirely independent of the trial may

be approached. If one attempt to find a nominated consultee is unsuccessful, we will not attempt further to recruit the participant.

The initial approach to potential participants/carers will come from the patient's responsible clinician or a member of the healthcare team in the clinic. Those individuals who provide outline permission will be contacted by a research nurse, who will assess eligibility and obtain consent. All research nurses will be trained in informed consent, including methods for assessing competence for consent, agreement to participant and obtaining advice from carers.

If the participant demonstrates a lack of capacity or competency to consent to this research and does not object, then the researcher will obtain advice from the carer, on whether the person who lacks capacity should take part in the project and what their past and present wishes and feelings would have been about taking part. All research staff taking consent will receive specific training on this issue.

Carers will also be invited to participate in the trial for the collection of data on carer burden. Their willingness to participate will not affect the inclusion or consent of the person with dementia (PWD) as a participant.

At each assessment visit the researcher will check that the participant still agrees to take part in the study

2.7 Recruitment and Randomisation

Design: The main trial is a multi-centred, randomised parallel group controlled trial with economic analysis. The unit of randomisation will be the individual patient, stratified by site and dementia severity (MMSE >10 for mild and moderate dementia). Participants will be randomised to (1) best practice usual care, or (2) best practice usual care plus a four-month group exercise intervention with a physical activity maintenance component.

Participants and settings: We will identify potential participants from the clinic attendances and review lists of Dementia Services in Coventry and Warwickshire, and Oxfordshire, Berkshire, Buckinghamshire and Northamptonshire. Potential participants will be people with mild to moderate dementia currently or recently receiving services (assessment and/or treatment) from secondary care services for dementia. This will include those newly diagnosed and those being followed up longer term. Potential participants will be screened for initial eligibility (from medical notes, clinic records and/or clinical consultations) and, if appropriate, given information about the trial. This will involve an initial approach from a member of the clinical team in secondary or primary care. Potential participants will be referred to the study research worker who will arrange an appointment to discuss the trial, answer any questions, take informed consent, undertake baseline assessments, arrange randomisation and appropriate follow on treatments as determined by the allocation.

Subjects will be randomised strictly sequentially, as subjects are eligible for randomisation.

Randomisation will be undertaken by the Randomisation service at WCTU. This is a telephone service available for randomisations during standard working hours Tel: 024 765 150402 (Mon-Fri, 9am to 5pm).

Carer participants will not be randomised; their inclusion is for observational purposes only.

2.8 Post-randomisation withdrawals and exclusions

Subjects may be discontinued from the trial treatment and/or the trial at any time without prejudice. Unless a subject explicitly withdraws their consent, they will be followed-up wherever possible and data collected as per the protocol until the end of the trial.

Participants who become unable to participate in the exercise intervention will withdraw from the intervention but will continue to be followed up at 6 and 12 months as per protocol.

Carers as participants may withdraw from the trial without this affecting the inclusion of the participant with dementia.

Documentation will be completed on withdrawal to confirm the date and reason for withdrawal.

2.9 Blinding

2.9.1 Methods for ensuring blinding

Randomisation, allocation concealment and masking: The random allocation sequence will be generated by an independent statistician using a random number generator, and implemented by a central telephone registration and randomisation service at the Warwick Clinical Trials Unit. Research workers will register participants after confirming eligibility and obtaining consent, thus ensuring allocation concealment. Neither intervention providers (DAPA physiotherapists) nor participants can be masked to treatment allocation. We will arrange for follow-up assessments to be conducted by different research workers to ensure investigator masking, and all study personnel involved with data entry, management and analysis will be masked until the final analysis is complete. We will undertake assessments of the success of masking.

2.10 Trial Intervention / Treatments

2.10.1 Trial Treatment(s) / Intervention

Research methods

- We propose to conduct a series of studies in preparation for the main trial. We will update a systematic review (authored by our group), undertake a pilot study and evaluate operational procedures, trial materials, and the acceptability of the intervention and its implementation. The main trial will evaluate the effects of adding the exercise/physical activity package to usual care for patients with mild to moderate dementia. Economic and qualitative studies will run parallel to the main trial. We describe research methods for the main trial first.
- Outcomes will be assessed at 6 and 12 months, to reflect the short-term and sustained effects of DAPA.

Planned interventions

- *Best practice usual care:* All participants will receive care as usual from the clinical service they attend. All of the services participating in our study provide best practice care in accordance with national guidance, including the relevant NICE guideline.
- *Exercise intervention:* The exercise intervention will be delivered in a group format, with up to 14 participants in each group. The programme will be provided in two, 1-hour sessions per week for 4 months, supplemented with between-session at-home exercises of at least one hour per week. Each participant will receive a brief assessment prior to entering the exercise class to determine initial dose. The intervention will be delivered in a secure environment, for example day centres where dementia respite care is provided already. This ensures adequate access and appropriate security. We will train physiotherapists to deliver the intervention, as although therapists are more expensive than exercise trainers, they have the specialist expertise to deal with dementia. Physiotherapists will be supported by a technical assistant as the groups are likely to be challenging to deliver.
- We have developed the training programme for physiotherapists, and have engaged substantial amounts of user input into the development of the intervention, which included a consultation forum co-ordinated by the Alzheimer's Society in Coventry. Subsequently we have undertaken a rigorous process evaluation alongside the implementation of the intervention within the OPERA study, which has included participant and carer observation and interviews to assess the acceptability of the intervention and its implementation.
- The most significant challenge is to develop a physical activity programme that people can adhere to after they have finished the structured part of the intervention. This will form an appreciable part of the pilot phase. We will link people to activities they enjoy and using behavioural strategies appropriate for people with memory impairment to promote adherence. Carers will play an important role, and many will want to assist in promoting adherence. However, we need to respect that not all carers will want to or be able to do this, and we will seek alternative options for these individuals. It is likely that we will use a counselling session at the end of the exercise programme, backed up with regular (up to monthly) phone calls to encourage adherence.

Pilot study, and evaluation of pilot and main study phases

Pilot study

The issues that need to be addressed by the pilot study are:

1. Is the size of the groups optimal, and do we need a physiotherapist and technical assistant for all classes?
2. Is the upper intensity level of the OPERA intervention sufficient to deliver a moderate aerobic challenge to participants?
3. Does the structured programme result in changes in physiological intermediary variables indicative of improved strength and aerobic conditioning?
4. Can we help participants make a successful transition to a sustainable pattern of physical activity at the end of the programme?

5. What is the participant and carer experience of the exercise programme, and how can we improve this?
6. Do the outcome measures capture issues important to users, and what is the likely uptake of the invitation to participate?

We will conduct a randomised pilot, and recruit at least one group of people with dementia to participate. As part of the process evaluation we will sample physiological data relating to cognition, aerobic strength and other physiological variables to determine the size and timing of response, and will evaluate physical activity levels using activity monitors during the structured programme, and afterward. All of the proposed measures will be sampled and will be undertaken during or immediately after the class.

Qualitative evaluation

Pilot evaluation

We will interview and observe participants and their carers to inform the development and evaluation of the intervention, gaining insight into barriers and facilitators to engagement, the experience of the intervention and acceptability. For this qualitative component, a researcher will observe the sessions, conduct short informal interviews with participants and carers, and those delivering the sessions. To further evaluate the intervention and its supporting materials, brief face to face or telephone interviews will be conducted with participants and their carers. In the pilot phase, we will include those with low or no attendance. Interviews will be recorded and transcribed verbatim. Data will be coded thematically using NVivo software, and analysed using framework analysis (Green et al 2004).

Main study evaluation

During the main phase of the trial, we will record the number of sessions each individual attended, and the intensity of exercise achieved. We will interview participants (approx n=15) of the intervention arm of the main trial 3 months after completion. Their main carer will also be invited. Ideally the interview with the participant and carer will be undertaken separately, although it is likely that most will want to be interviewed jointly (Powell et al 2010). These interviews will focus on the impact of the intervention on living with dementia including changes in wellbeing, maintenance of exercise between group sessions and after completion of the intervention. In the main study we will only include participants who have good attendance. Transcription and analysis will mirror processes in pilot phase (above)..

More details on the exercise intervention we will test

We have developed a comprehensive exercise programme to prevent and manage depression in older people living in long term care settings, and this is being tested in the OPERA study (HTA 06/02/01). Many of the mechanisms targeted for the management of depression are similar to those used to target dementia, and we will use the OPERA intervention as the foundation for the DAPA trial. The intervention is designed for group-based implementation by a physiotherapist, and has three levels of difficulty to fit with the requirements of those who cannot stand well alone, those who can stand with support, and those who are mobile and functioning relatively well. It is likely that the individuals we will recruit in the DAPA study will fall into the upper functioning cohort.

In the pilot study we will test to ensure a sufficient aerobic challenge, and refine this further if required. The OPERA intervention is delivered to music, which is known to stimulate compliance within sessions and enhance enjoyment. The intervention is delivered by physiotherapists who are experienced in managing people with dementia. For the DAPA study, we will supplement each session with a technical assistant because the participants are likely to be more mobile, and potentially more difficult to manage in a group.

The DAPA intervention will include the addition of an element to ensure self-sustaining exercise in the community. In the pilot study we will evaluate whether participants can be matched to existing community programmes. Generally exercise on prescription, health walks and similar schemes do not cater for people with significant levels of cognitive impairment. Exercise programmes are provided by some local branches of voluntary organisations, but provision is sporadic. We need to explore the acceptability of a home based activity programme implemented in collaboration with carers, family and friends, and to design the motivational materials needed to ensure compliance.

Much time and cost will be saved by building on the materials, manuals, CDs, training programme and expertise gained in the OPERA intervention. The OPERA exercise programme has been delivered to over 300 older residents of care homes, the majority of whom scored in the cognitive impairment range on MMSE which we will be using for this study. There have been no adverse events resulting from participation, and most people report enjoying sessions.

2.10.2 Compliance/Contamination

During the main phase of the trial, we will record the number of sessions each individual attended, and the intensity of exercise achieved.

We will periodically observe the consent process and baseline and follow-up assessments. The clinical research fellow based at Warwick will have responsibility for quality control of the interventions. The clinical research fellow will periodically make quality control visits to observe the group exercise sessions and will ensure quality control for the implementation of organisational change. Quality assurance checks will be undertaken by the WCTU to ensure the integrity of randomisation, study entry procedures and data collection.

3. METHODS AND ASSESSMENTS

3.1 Schedule of intervention and data collection

Table 1 Trial events

Visit	1	Supervised Exercise	Unsupervised Exercise	2	3
Visit Window (No. Weeks \pm No. Days)	Baseline assessment	32 sessions twice weekly for 4 months	1 hour per week for first 4 months then 3 hours per week for the subsequent 8 months	6 m (\pm 1 m) After Visit 1 Main Trial only	12 m (\pm 1m) After Visit 1 Main Trial only
Informed consent	✓				
Medical history	✓				
Inclusion/exclusion criteria	✓				
Intervention		✓	✓		
Demographic data	✓ (main trial only)				
Cognitive/ Function MMSE/ BADL	✓			✓	✓
Quality of Life EQ5D/	✓			✓	✓
Dementia Quality of Life NPI/CSDD	✓			✓	✓
Carer Burden ZBI	✓			✓	✓
Adverse events		✓		✓	✓

4. ADVERSE EVENT MANAGEMENT

4.1 Definitions

4.1.1 Adverse Events (AE)

An adverse event is defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with this treatment.

4.1.2 Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Events

A serious adverse event is an AE that fulfils one or more of the following criteria:

- Results in death
- Is immediately life-threatening
- Requires hospitalisation or prolongation of existing hospitalisation
- Results in persistent or significant disability or incapacity
- Is a congenital abnormality or birth defect
- Is an important medical condition.

4.2 Reporting SAEs

We will define a serious adverse event as any fracture, death or hospitalisation that occurs as the result of an incident during, or within two hours of completing the exercise sessions or follow-on physical activities.

SAEs and SUSARs will be reported using the SAE form. The Exercise Physiotherapist for each exercise intervention must report any SAEs and SUSARs to the Trial Co-ordinating Centre within 24 hours of them becoming aware of it. The SAE form should be completed and faxed to 02476 150549. The trial co-ordinator will liaise with the clinician to compile all the necessary information. The Trial Co-ordinating Centre is responsible for reporting adverse events to the sponsor and ethics committee within required timelines.

The causality of SAEs (i.e. relationship to trial treatment) will be assessed by the Chief Investigator(s) and this will be recorded on the SAE form.

All SAEs will be recorded in the trial database and reported to and reviewed by the Trial DMEC throughout the Trial.

All SAEs will be followed up to resolution.

4.3 End of Trial

The trial will end when 728 patients have been recruited and completed their 12 month follow-up. The trial will be stopped prematurely if:

- Mandated by the Ethics Committee

- Following recommendations from the Data Monitoring and Ethics Committee (DMEC)
- Funding for the trial ceases

The Main Research Ethics Committee (MREC) will be notified in writing if the trial has been concluded or terminated early.

5. DATA MANAGEMENT

Personal data collected during the trial will be handled and stored in accordance with the 1998 Data Protection Act.

Participants will be identified using a unique trial number. The trial number for the participant with dementia (PWD) and the carer as participant will be linked for cross identification purposes.

Personal identifying information will be held at WCTU, when received in response to the invitation. Personal contact details of trial participants and their carers will be needed to organise the baseline and follow-up meetings and send information about dates, venues and timings for exercise classes. This information will be filed separately from all other trial information and each participant and their carer will be assigned a unique trial number. We will retain paper records of participant & carer details.

5.1 Data collection and management

The Case Report Forms (CRFs) will be designed by the Trial Co-ordinator in conjunction with the Chief Investigator, Co-investigators and Statistician. Original copies will be sent to WCTU, with copies of CRFs held by physiotherapists in relation to the exercise intervention. Data will be entered onto a WCTU database by a member of the Trial team. Data will be subject to validity checks and additional data checking procedures to assure quality of data entry.

5.2 Database

The database will be set up by the Programming Team at WCTU and all specifications (i.e. database variables, validation checks, screens) will be agreed between the programmer, statistician and trial co-ordinator.

5.3 Data Storage

All essential documentation and trial records will be stored by WCTU in compliance with the applicable regulatory requirements and access to stored information will be restricted to authorised personnel.

5.4 Archiving

Trial documentation and data will be archived for at least five years after completion of the trial.

6. STATISTICAL ANALYSIS

A fully specified data analysis plan, including frequency of analyses and pre-planned sub-group analyses, will be developed in the early phases of the trial and approved by the DMEC. Data will be summarised and reported in accordance with CONSORT guidelines for randomised controlled trials (Shultz et al 2010), and we will use intention-to-treat analyses.

Treatment effects: Hierarchical regression models will be used to estimate the treatment effects (with 95% confidence intervals), and will be adjusted for important co-variables (age, sex and baseline MMSE). We will include estimation of and adjustment for therapist effects. Pre-specified sub-group analyses will examine the interaction of treatment assignment with severity of cognitive impairment (MMSE ≥ 20 and < 20) and gender will be conducted using formal tests of interaction (Brookes et al. 2001). We will explore dose dependency in a secondary analysis, by reporting effect across quartiles of dose received, and will test for trend in the effect across the doses.

We will estimate the group effects in the trial, if this is possible. Hierarchical analyses adjusting for group effect will give us insight into whether the group structure is contributing to the treatment effect.

Economic analysis: The most significant formal costs associated with dementia are the costs of social and long term care (Quentin et al 2010). Hospitalisation costs are also likely to occur, particularly related to falls and injuries (Rizzo et al 1998). The economic analysis will therefore focus on the following major components of costs: NHS primary and secondary care, local authority care, the costs to other agencies or organisations, costs associated with institutional care and home care support (summarised in Table 2). Intervention costs will reflect the costs necessary to implement the DAPA physical activity, including development and training, overheads, equipment, and staff-related expenses.

Two economic evaluations will be undertaken – a *within trial evaluation* will compare the outcomes and cost during follow up and, secondly, a *decision analytic cost effectiveness model* will be used to estimate the expected incremental cost per quality-adjusted life year (QALY) gained for the DAPA interventions in comparison to best practice usual care. For both analyses, the perspective will be that of the UK NHS and social services. The potential impact of adopting a societal perspective on incremental cost-effectiveness ratios will be tested in sensitivity analyses using data on informal and indirect costs provided by carers at 6 and 12 months.

The within trial analysis will compare the costs and outcomes between the study arms at the end of follow up. The primary outcome measure will be the QALY. Utility weights will be taken from the UK General Population tariff for the EQ-5D (Dolan 1997, Kind et al 1999). Unit costs will be taken from national databases including the NHS reference costs and the PSSRU costs of health and social care. Where national unit cost estimates are not available unit costs will be estimated using established accounting methods in consultation with Trusts recruiting to the study. In line with current recommendations for best practice in economic analyses, costs and outcomes will be discounted at 3.5% per annum. Probabilistic

sensitivity analysis will be undertaken using the non-parametric bootstrap. We will use the Client Services Receipt Inventory as a framework for resource data capture (Beecham & Knapp 1992).

The decision analytic cost effectiveness analysis model will use a lifetime time horizon to capture the full impact of any mortality and health-related quality of life differences on the long term cost effectiveness. It is likely that the model will have a semi-markov structure to capture the time trend in the underlying risk of mortality, health related quality of life, and costs of care. The methods for estimating health related quality of life and utility, unit costs and discounting will be the same as for the within trial analysis. Probabilistic sensitivity analyses will be undertaken using Monte Carlo simulation techniques. The outputs reported from the analysis will be the same as for the within trial analysis.

7. TRIAL ORGANISATION AND OVERSIGHT

7.1 Ethical conduct of the trial

Ethical arrangements: The study will obtain all necessary ethical permissions and NHS Research and Development approvals before commencing. All data will be stored securely and anonymised in accordance with Data Protection Act, and the trial will be conducted in compliance with the principles of MRC GCP guidelines, the Declaration of Helsinki and other requirements as appropriate. Our team has considerable experience of research involving people with dementia (e.g. DOMINO- AD, and OPERA) and in developing appropriate consent procedures in accordance with legal and regulatory requirements.

Risks and benefits: All participants will have access to usual care, and thus no treatment will be withheld from trial participants. There is some limited evidence of a very small increased risk of injury as a result of becoming more physically active. In our physical activity programme, however, healthcare professionals tailor progressive exercises to individual need/ability, and deliver the programme to small groups of participants in a supervised and safe context.

All participants may benefit from the provision of additional 'usual care' monitoring. Intervention participants may also benefit from the wide range of positive effects associated with increased physical activity. A successful trial will also yield substantial benefits for others. Either we will demonstrate that DAPA is clinically effective and that its wider implementation would benefit patients, carers and society more generally, or we will demonstrate that DAPA is ineffective or not cost-effective, thus allowing NHS resources to be re-directed to other more effective interventions.

Informing potential participants of risks and benefits: The patient information leaflets will provide potential participants with information about the possible risks and benefits of taking part in the trial. Potential participants will be given the opportunity to discuss the trial with the research nurse. We will inform participants, their carers and GPs/consultants if new information comes to light that could affect their willingness to participate in the trial.

Research Governance The trial will be conducted in accordance with the Standard Operating Procedures of Warwick Clinical Trials Unit. A Trial Steering Committee (TSC) and a Data Monitoring and Ethics Committee (DMEC) will be convened, and each will have at least 3 independent members. In addition, each committee will have a lay member with relevant experience of dementia and dementia care services.

7.2 Sponsor

The University of Warwick will act as Sponsors for the trial.

7.3 Indemnity

Staff employed by the NHS will be covered by the Clinical Negligence Scheme for NHS Trusts. Staff employed by the University of Warwick will be covered by the University's trial insurance. Negligent harm cover will be provided by standard NHS arrangements (HSGG(96)48). NHS Indemnity does not give indemnity for compensation in the event of non-negligent harm, so no specific arrangements exist for non-negligent harm for this trial.

7.4 Trial timetable and milestones

Recruitment rate

In the main study, we have planned for a recruitment period for each site of 12 months, giving an overall target of 8.5 patients per centre per month. This will be moderated according to the size of the centre, and phase of the trial. The sites will be launched in phases over the first three months of the trial. We will aim to launch 3 sites per month for the first 2 months (and continue recruiting in the pilot sites).

Table 2: DAPA recruitment targets

Target	Trial Recruitment Period (Month)													
	12	13	14	15	16	17	18	19	20	21	22	23	24	25
Sites	1	4	7	7	7	7	7	7	7	7	7	7	6	3
Monthly	16	56	80	56	56	56	56	56	56	56	56	56	48	24
Cumulative	16	72	152	208	264	320	376	432	488	544	600	656	704	728

Recruitment contingency: We have 3 reserve clinical sites if the uptake of the invitation to participate were 20% as opposed to 30% as we planned for (South Warwickshire, Aylesbury, Brackley). We have based the rates on a 12 month recruitment period for each site, although our timetable has a few months contingency if delays are incurred.

Project timetable and milestones

This project will require 54 months to complete (Table 3). We are confident to progress into delivering the intervention in the pilot study early on – the highest level of the OPERA intervention should result in the correct training stimulus, and we can monitor and moderate this as we progress. We will update the reviews ahead of the project, and at the same time as conducting the pilot exercise classes. We need to test the feasibility of transferring to community and other sustainable types of exercise, and this will occur at about 9 months in the overall project plan. At this point we will triangulate the information, from reviews and our experience of delivering the intervention, and make any necessary amendments to the intervention training manual and materials. We will also have evaluated how many people are likely to accept the invitation to participate in the trial and have refined the projections for the trial. The feasibility of the study would be known at this point, and we can agree with the funders whether it is desirable to continue.

Our timetable is quite tight, and we have assumed an immediate roll forward. We will launch the main trial at 12 months. We have a bank of experienced therapists who have already been trained in delivering the OPERA intervention, although we will need to identify and train therapists at more remote sites. The trial will recruit participants from month 12, finishing by month 27 (allowing for some contingency above and beyond the recruitment targets set). Final 12 month follow up will be complete by up to month 42. Data analysis, and report writing will be from month 45 onward. Summary results will be presented to DMEC, TSC and user groups for comment, a full report will be prepared and submitted to HTA, and other dissemination activities will be undertaken.

7.5 Administration

The trial will be coordinated at Warwick Clinical Trials Unit. A trial coordinator will be responsible for the day to day management of the trial. A clinical research fellow will be responsible for the day to day work to update the systematic reviews, refine the intervention, train the physiotherapists and ensure there are sufficient numbers of therapists available, ensure the quality of the intervention, and collect data and report on fidelity of the intervention. A second research fellow will be appointed to assist with these activities, the qualitative study, and fidelity modelling during the main trial. Clinical guidance will be provided by Dr Sheehan (Associate Clinical Professor, The University of Warwick), Dr McShane (Clinical Lead, DeNDRoN) & Mrs Nicola Atherton (Research Fellow, the University of Warwick).

7.6 Trial Management Group (TMG)

The Trial Management Group, consisting of the project staff and investigators involved in the day-to-day running of the study, will meet regularly throughout the project. Significant issues arising from management meetings will be referred to the TSC or Investigators, as appropriate.

7.7 Trial Steering Committee (TSC)

The trial will be guided by a group of respected and experienced dementia personnel and trialists as well as 'lay' representatives. The TSC will have an independent Chairperson and a

minimum of three independent members. Face to face meetings will be held at regular intervals determined by need but not less than once a year. Routine business is conducted by email, post or teleconferencing.

The Steering Committee, in the development of this protocol and throughout the trial will take responsibility for:

- Major decisions such as a need to change the protocol for any reason
- Monitoring and supervising the progress of the trial
- Reviewing relevant information from other sources
- Considering recommendations from the DMEC
- Informing and advising on all aspects of the trial

7.8 Data Monitoring and Ethics Committee (DMEC)

The Data Monitoring Committee will consist of independent experts with relevant clinical research, and statistical experience. During the period of recruitment into the trial, interim analyses of the accumulating data will be supplied, in strict confidence, to the DMC, along with any other analyses that the committee may request. The frequency of these analyses will be determined by the committee.

7.9 Essential Documentation

A Trial Master file will be set up and held securely at the coordinating centre, in accordance with WCTU SOPs.

8. MONITORING AND QUALITY ASSURANCE OF TRIAL PROCEDURES

The trial will be conducted in accordance with the Standard Operating Procedures of Warwick Clinical Trials Unit. A Trial Steering Committee (TSC) and a Data Monitoring and Ethics Committee (DMEC) will be convened, and each will have at least 3 independent members. In addition, each committee will have a lay member with relevant experience of dementia and dementia care services.

The Sponsor will ensure investigator(s)/institutions will permit trial-related monitoring, audits, REC review and regulatory inspections, providing direct access to source data/documents.

A risk assessment of the project will be undertaken by the trial team and a Data Monitoring Plan produced. Monitoring will be conducted in accordance with this Data Monitoring Plan throughout the trial. A Data Management Plan will also be followed throughout the trial.

9. DISSEMINATION AND PUBLICATION

The results of the trial will be reported first to trial collaborators. The main report will be drafted by the trial co-ordinating team, and the final version will be agreed by the TSC before submission for publication, on behalf of the collaboration. The trial will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines.⁽³⁹⁾ The main publications will be the report to the funding body (HTA Monograph) and a journal publication. In addition, the results will be presented at international conferences.

A policy for authorship of trial publications will be drafted and agreed by the investigators, in accordance with the WCTU Standard Operating Procedure 22 (Publication and Dissemination).

At final contact during the study participants will be informed that results will be posted on study websites. If they request to have further details we will endeavour to accommodate this.

10. FINANCIAL SUPPORT

The trial is funded by the NIHR Health Technology Assessment Programme, grant number 09/80/04.

11. PROTOCOL AMENDMENTS

12. REFERENCES

- Abbott et al. Walking and Dementia in Physically Capable Elderly Men. *JAMA* 2004;292:1447-1453.
- Alexopolous GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. *Biological Psychiatry* 1988;23:271-284.
- Baker et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. *Arch Neurol.* 2010 Jan;67(1):71-9
- Beecham JK, Knapp MRJ (1992) *Measuring Mental Health Needs*. London: Gaskell
- Black et al. Scales as outcome measures for Alzheimer's disease. *Alzheimer's & Dementia.* 2009;5:324-339.
- Brookes et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. *HTA* 2001;5(33).
- Brown et al. Self-administered cognitive screening test for detection of Alzheimer's disease: cross-sectional study. *BMJ* 2009;338:2030
- Bucks et al. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. *Age & Ageing* 1996;25:113-120.
- Cummings et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994;31:2308-2314.
- Deslandes et al. Exercise and Mental Health: Many Reasons to Move. *Neuropsychobiology* 2009;59:191-198
- Dolan P. Modelling valuations for EuroQoL health states. *Med Care* 1997;35(11):1095-108.
- Erickson KI, Kramer AF. (2009). Aerobic exercise effects on cognitive and neural plasticity in older adults. *British Journal of Sports Medicine*, 43:22-24.
- Etgen et al. Physical activity and incident cognitive impairment in elderly persons. *Arch Intern Med.* 2010;170(2):186-193.
- EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. *Health Policy* 16:199-208
- Geda et al. Physical exercise, aging, and mild cognitive impairment. *Arch Neurol.* 2010;67(1):80-86.
- Green J and Thorogood N. *Qualitative Methods for Health Research*. 2004 London. Sage.
- Higgins J, Green S (Eds). *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.0.2. (updated September 2009) <http://www.cochrane-handbook.org/>
- Folstein et al.: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research* 1975, 12:189-198.

Kind et al. Variations in population health status: results from a United Kingdom national questionnaire survey. *BMG* 1998;316:736-741.

Lautenschlager et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer's disease: a randomized trial. *JAMA* 2008;300(9):1027-37

Life Study Investigators. Effects of a Physical Activity Intervention on Measures of Physical Performance: Results of the Lifestyle Interventions and Independence for Elders Pilot (LIFE-P) Study. *Journal of Gerontology* 2006;61(11):1157-1165.

Lindesay et al. The second Leicester survey of memory clinics in the British Isles. *International Journal of Geriatric Psychiatry*, 2002; 17:41-47.

Liu-Ambrose T, Donaldson G. Exercise and cognition in older adults: is there a role for resistance training programmes? *Br J Sports Med* 2009;43:25-27

Logsdon et al. Assessing quality of life in Alzheimer's disease: patient and caregiver reports. *Journal of Mental Health and Aging* 1999;5 :21-32

Logsdon et al. Making physical activity accessible to older adults with memory loss: A feasibility study. *The Gerontologist* 2009;49(1): S94-S99.

Luce et al. How do memory clinics compare with traditional old age psychiatry services? *International Journal of Geriatric Psychiatry*, 2001; 16:837-845.

Luengo-Fernandez et al. Dementia 2010: The economic burden of dementia and associated research funding in the United Kingdom. Alzheimer's Research Trust [2010. www.dementia2010.org](http://www.dementia2010.org)

Lytle et al. Exercise level and cognitive decline: the MoVIES Project. *Alzheimer Dis Assoc Disord.* 2004;18:57-64.

Molnar et al. Systematic Review of Measures of Clinical Significance Employed in Randomized Controlled Trials of Drugs for Dementia. *Journal of the American Geriatrics Society.* 2009; 57(3): 536-546.

Moniz-Cook et al. A European consensus on outcome measures for psychosocial intervention research in dementia care. *Aging & Mental Health* 2008;12(1):14-29.

NICE clinical guideline 42. National Institute for health and Clinical Excellence. (2006) Dementia: supporting people with dementia and their carers in health and social care.

NICE Living well with dementia: a National dementia Strategy (2009) Department of Health

Powell et al. (In Press) New networked technologies and carers of people with dementia: an interview study. *Ageing & Society*;30:1073-1088.

Quentin et al. Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs. *Acta Psychiatr Scand* 2010;121:243-259.

Rizzo et al. Health care utilization and costs in a Medicare population by falls status. *Medical Care* 1998;36:1174-1188.

Rockwood et al. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. *BMC Neurology* 2007, 7: 26doi:10.1186/1471-2377-7-26

Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. *PLoS Med* 2010;7(3):e1000251. doi: 10.1371/journal.pmed.1000251

Weuve et al. Physical Activity, Including Walking, and Cognitive Function in Older Women. *JAMA* 2004;292(12):1454-1461.

Zarit SH, Reever K, Bach-Peterson J (1980) Relatives of impaired elderly: correlates of feelings of burden. *Gerontologist* 20:649-655.

13. APPENDICES

Table 3. Project timetable

Project Activity (Trial month)	<0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54
Recruit research staff	*			*															
Ethics appraisal	*				*														
Update systematic review	*	*																	
Design sustainable physical activity prog.	*	*																	
Pilot study		*	*	*	*														
Structured exercise		*	*																
Physical activity			*	*															
Pilot study evaluation				*	*														
Site set-up/approvals			*	*	*														
Recruit / train DAPA providers				*	*														
Main trial					*	*	*	*	*	*	*	*	*	*	*	*			
Recruitment period					*	*	*	*	*	*									
Exercise groups					*	*	*	*	*	*	*								
6-month follow-up							*	*	*	*	*	*							
12-month follow-up									*	*	*	*	*	*	*				
Data analysis			*	*	*											*	*	*	*
Economic appraisal			*	*	*											*	*	*	*
DMEC meeting			*			*			*			*			*			*	
TSC meeting				*			*			*			*			*			*
Monitoring reports			*		*		*		*		*		*		*		*	*	*
HTA monograph/pubs					*	*												*	*